Chronic kidney disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SGLT2 24
• GLP-1 8
• NLRP3 0
• NRF2 1
• PI3K 0
• APOL1 3
• STAT3 1
• AKT 0
• mTOR 1
• PPAR 0
• AMPK 0
• SIRT1 0
• HIF-1 0
• TLR4 0
• MAPK 0
• STING 0
• CTNNB1 0
• TP53 0
• ERK 0
• GPX4 0
• IL-6 3
• VEGF 0
• JAK 0
• IL-1 1
• JNK 0
• TNF 1
• DPP-4 0
• EGFR 0
• YAP 0
• FGFR 0
• PCSK9 0
• APOE 0
• PINK1 0
• TFEB 0
• BCMA 3
• HMGB1 0
• HSP90 0
• BDNF 0
• GIP 0
• CD40 0
• CD47 0
• COX-2 0
• IL-17 1
• PKM2 0
• PSMA 0
• ABL1 0
• CCR5 0
• EZH2 0
• METTL3 0
• MMP-9 0
• PKD1 0
• PTEN 0
• SNCA 0
• ANGPTL3 0
• BCL-2 0
• CD19 1
• CD38 0
• CDK4/6 0
• CXCR4 0
• FTO 0

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R01

  Mobile Strategy for Improving Eye Health of Kidney Patients Treated with Dialysis (SIGHT)

  University of Washington· Seattle, United States· US$1,383,760 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · K08

  Natural killer T cells in acute cardiorenal syndrome

  Oregon Health & Science University· Portland, United States· US$160,584 awarded in fiscal year 2026· until Jul 2031

• NIH NIA · R43

  Optimization of brain-permeable CK2 inhibitors to inhibit neuroinflammation and metabolic dysfunction in Alzheimer's disease

  Talos Therapeutics, Inc.· San Diego, United States· US$497,554 awarded in fiscal year 2026· until Sept 2027

• NIH NIDDK · R01

  The Interaction between Food Craving and Food Choice in Humans: A Computational Intracranial Electrophysiological Study

  Icahn School of Medicine at Mount Sinai· New York, United States· US$854,983 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · R01

  mRNA Splicing in Podocyte Biology and Glomerular Disease

  State University New York Stony Brook· Stony Brook, United States· US$755,725 awarded in fiscal year 2026· until Jun 2030

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the gene regulation of oxygen homeostasis and human fitness (ErythrO2Reg)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,500,000· until Mar 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-generation therapeutics for vascular diseases (TIE2gether)

  Helsingin Yliopisto· Helsinki, Finland· EU contribution €4,273,568· until Jan 2031· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Formaldehyde crosslink exposure and genomic ageing (FORCE)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €2,693,628· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Early Inflammation in Fibrotic Niches of Chonic Kidney Disease (InFibrosis)

  Universite Paris Cite· Paris, France· EU contribution €1,498,100· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Direct implication of the Calcium Sensing Receptor in Vascular Calcifiction and Atherosclerosis in Chronic Kidney Disease (AtheroCaSR)

  Cardiff University· Cardiff, United Kingdom· EU contribution €325,435· until Feb 2029

10 of 1,568 running projects, newest first. Listed amounts together: US$854.3m + €145.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Genetic Testing to Understand and Address Renal Disease Disparities Across the United States

  NCT04191824· Duke University· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 29
• Organoids 10
• Mendelian Randomization Analysis 78
• CRISPR-Cas Systems 5
• Gene Expression Profiling 88
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 2
• Exome Sequencing 19
• Proteomics 103
• Metabolomics 91
• Mass Spectrometry 18
• Flow Cytometry 10
• Immunohistochemistry 19
• Liquid Biopsy 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 70
• Machine Learning 176
• Deep Learning 23
• Cohort Studies 556
• Genome-Wide Association Study 79

• Detection of the NPHP4 c.2999_3005del (p.Asn1000SerfsTer4) variant in an Iranian family with nephronophthisis-4.

  Mol Genet Genomics, Jul 2026

• Systematic analysis of homozygous autosomal copy number losses in exomes improves diagnostic yield and uncovers ultra-rare recessive disorders.

  Eur J Hum Genet, Jun 2026

• Monogenic kidney disease and monogenic diabetes are present in renal clinic patients with non-genetic diagnoses.

  Sci Rep, May 2026

• Clinical and Molecular characteristics of kidney and urinary tract congenital anomalies in a cohort of Egyptian patients using whole-exome sequencing.

  Mol Biol Rep, May 2026

• A Whole-Exome Sequencing-Based Exploration of Chronic Kidney Disease of Unknown Etiology (CKDu) in an Endemic Population in Sri Lanka.

  Int J Mol Sci, Apr 2026

• Prevalence and Genetic Spectrum of Inherited Kidney Diseases: A Chinese Cohort Study.

  Kidney360, Apr 2026

• Genetic testing in kidney transplantation and living kidney donor risk assessment.

  Kidney Int, Mar 2026

• FREM2 as a candidate gene for posterior urethral valves: Evidence from a case-parent cohort.

  J Pediatr Urol, Mar 2026

• Epigenetic corepressor BCORL1 predominates as a driver of clonal hematopoiesis of indeterminate potential in patients undergoing chronic hemodialysis: a multicenter cohort study.

  Hum Genomics, Mar 2026

• Early-onset kidney failure in a girl with autosomal dominant tubulointerstitial kidney disease due to a de novo UMOD variant.

  CEN Case Rep, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.